Francis E Lotrich1, Bruce G Pollock, Margaret Kirshner, Robert F Ferrell, Charles F Reynolds Iii. 1. NIMH Advanced Center in Interventions and Services Research for Late-Life Mood Disorders and the John A. Hartford Foundation Center of Excellence in Geriatric Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. lotrichfe@upmc.edu
Abstract
OBJECTIVE: To investigate whether variable antidepressant response may be influenced by an interaction between the serotonin transporter promoter polymorphism (5-HTTLPR) and antidepressant concentration. METHODS: Elderly subjects with depression treated with paroxetine (n = 110) were genotyped and assessed with the Hamilton Rating Scale for Depression (HAMD). A mixed-effect analysis of repeated measures was used. RESULTS: There was an interaction between early paroxetine concentration and 5-HTTLPR genotype on symptomatic improvement over 12 weeks (F(18,59.5) = 1.8, p < 0.05), as well as main effects of both paroxetine concentration (F(68,55.3) = 2.4, p < 0.005) and genotype (F(2,74.2) = 5.7, p < 0.005). Paroxetine concentrations were correlated with change in HAMD scores after 2 weeks of treatment in subjects with the short (s) allele (r = 0.31, p < 0.05) but not in subjects homozygous for the long (l) allele. CONCLUSION: The results demonstrate a concentration-response relation for paroxetine in late-life depression and support the hypothesis for both a direct main effect and a moderating influence of 5-HTTLPR alleles on this concentration-response relation.
OBJECTIVE: To investigate whether variable antidepressant response may be influenced by an interaction between the serotonin transporter promoter polymorphism (5-HTTLPR) and antidepressant concentration. METHODS: Elderly subjects with depression treated with paroxetine (n = 110) were genotyped and assessed with the Hamilton Rating Scale for Depression (HAMD). A mixed-effect analysis of repeated measures was used. RESULTS: There was an interaction between early paroxetine concentration and 5-HTTLPR genotype on symptomatic improvement over 12 weeks (F(18,59.5) = 1.8, p < 0.05), as well as main effects of both paroxetine concentration (F(68,55.3) = 2.4, p < 0.005) and genotype (F(2,74.2) = 5.7, p < 0.005). Paroxetine concentrations were correlated with change in HAMD scores after 2 weeks of treatment in subjects with the short (s) allele (r = 0.31, p < 0.05) but not in subjects homozygous for the long (l) allele. CONCLUSION: The results demonstrate a concentration-response relation for paroxetine in late-life depression and support the hypothesis for both a direct main effect and a moderating influence of 5-HTTLPR alleles on this concentration-response relation.
Authors: Robert R Bies; Yan Feng; Francis E Lotrich; Margaret A Kirshner; Steven Roose; David J Kupfer; Bruce G Pollock Journal: J Clin Pharmacol Date: 2004-12 Impact factor: 3.126
Authors: J D Amsterdam; J Fawcett; F M Quitkin; F W Reimherr; J F Rosenbaum; D Michelson; M Hornig-Rohan; C M Beasley Journal: Am J Psychiatry Date: 1997-07 Impact factor: 18.112
Authors: Gwenn S Smith; Francis E Lotrich; Anil K Malhotra; Annette T Lee; Yilong Ma; Elisse Kramer; Peter K Gregersen; David Eidelberg; Bruce G Pollock Journal: Neuropsychopharmacology Date: 2004-12 Impact factor: 7.853
Authors: Jeffrey H Meyer; Alan A Wilson; Sandra Sagrati; Doug Hussey; Anna Carella; William Z Potter; Nathalie Ginovart; Edgar P Spencer; Andy Cheok; Sylvain Houle Journal: Am J Psychiatry Date: 2004-05 Impact factor: 18.112
Authors: M C Mauri; V Laini; A Bitetto; L Boscati; M Scalvini; L Mapelli; R Rudelli Journal: Int J Psychiatry Clin Pract Date: 1999 Impact factor: 1.812
Authors: Eric J Lenze; Alison M Goate; Petra Nowotny; David Dixon; Peichang Shi; Robert R Bies; Francis K Lotrich; Bruce L Rollman; M Katherine Shear; Paul A Thompson; Carmen Andreescu; Bruce G Pollock Journal: J Clin Psychopharmacol Date: 2010-12 Impact factor: 3.153